



## In the News

To cite this article: (1998) In the News, Oncology Issues, 13:1, 32-32, DOI: [10.1080/10463356.1998.11904732](https://doi.org/10.1080/10463356.1998.11904732)

To link to this article: <https://doi.org/10.1080/10463356.1998.11904732>



Published online: 18 Oct 2017.



Submit your article to this journal [↗](#)



Article views: 2



View related articles [↗](#)

## ADMINISTRATOR ONCOLOGY SERVICES

### Baptist Memorial Health Care Corporation

Baptist Memorial Health Care Corporation, one of the largest and most prestigious health care systems in the country, has a unique leadership opportunity for an Administrator of the Oncology Services. Responsibilities include strategic business planning for oncology services, program development, oversight of clinical cancer research, development of early detection/prevention strategies, and design of community awareness and educational offerings.

#### Qualifications include:

- 3-5 years' progressive, outcome-oriented management experience with an excellent overall knowledge of oncology services. Degree required; Master's Degree and clinical experience preferred.
- Proven success in the areas of cancer program development, marketing, strategic planning, operational leadership, and fiscal management.
- Excellent interpersonal skills to facilitate a collaborative interdisciplinary team approach in development of a full spectrum of oncology programs/services throughout a large metropolitan market.

The Baptist Memorial Health Care Corporation is committed to building one of the most comprehensive cancer programs in the nation to meet the diverse health care needs of the communities we serve. If you are interested in this outstanding leadership position, and your background meets our organizational needs, please forward your resume and salary requirements:

Baptist Memorial Health Care Corporation  
Corporate Human Resources  
20 S. Dudley, Ground Floor  
Memphis TN 38104

(901) 227-2880 (phone) (901) 227-5388 (fax)  
Attn: Dee Banta, Director, Human Resources

Equal Opportunity Employer

### CALL FOR MULTIPLE MYELOMA PATIENTS

The National Cancer Institute is sponsoring a multi-center clinical trial to examine the use of a new agent to overcome chemotherapy resistance in multiple myeloma patients. The trial will study a new treatment in which PSC 833, a new cyclosporin D analog, plus vincristine, doxorubicin, and dexamethasone (VAD), is compared with VAD alone in the treatment of relapsing or refractory multiple myeloma. The study began accepting patients in March 1997, but is still seeking patients throughout the United States and Canada. The Eastern Cooperative Group (ECOG) is coordinating the trial, with participation by the Southwestern Oncology Group (SWOG), Cancer and Leukemia Group B (CALGB), and the National Cancer Institute of Canada's Clinical Trials Group (NCIC CTG).

"Drug resistance poses a significant obstacle in the treatment of multiple myeloma," explained William R. Friedenber, M.D., Marshfield Cancer Center, Marshfield, Wisc., and ECOG's multiple myeloma committee co-chair. "This compound—PSC 833—which is designed to overcome MDR [multidrug resistance], could possibly offer a second chance to patients who once responded to chemotherapy, but then had to stop because their malignant tumors had become resistant to anticancer treatment. If it works in multiple myeloma, it could also work in other cancers that develop MDR."

The study is seeking 360 patients. Physicians interested in registering patients should contact the ECOG Coordinating Center at 617-632-3610. All study participants must be at least eighteen years old with a diagnosis of measurable multiple myeloma.

### NEW PATIENT BROCHURES AVAILABLE!

Most newly diagnosed cancer patients don't know what a clinical trial is, let alone how to enter one. A new twenty-eight-page patient brochure produced by the National Cancer Institute explains in easy-to-understand language why clinical trials are important, how they are conducted, and how to take part. Unlimited quantities of "What Are Clinical Trials All About?" are available free of charge. Just fax your request to the Publication Ordering Service, National Cancer Institute, at 301-330-7968.

"Genetic Testing for Breast Cancer Risk: It's Your Choice" is an eight-page booklet that provides patients with a general overview on testing for breast and ovarian cancer risk. The publication and fact sheet accompany a fourteen-minute video, narrated by ABC News Correspondent Cokie Roberts.

The booklet and video are produced by the National Action Plan on Breast Cancer (NAPBC), a collaboration of government agencies, consumers, and health professionals from various disciplines. Distribution of the materials is supported, in part, by the Susan G. Komen Foundation. To receive copies, contact Shanna Duncan at 301-468-6555, ext. 3999. ☐